Issue : The Pharmaceutical Journal, 9/16 August 2014, Vol 293, No 7822/3
Anafranil overdose Subscription
The summary of product characteristics for Anafranil (clomipramine hydrochloride; Novartis) slow-release tablets 75mg now states that rare cases of pharmacobezoar, of varying severity including fatal outcome, have been reported in association with overdose of sustained release Anafranil. Further information about the pharmacobezoar is available in the updated SPC.
Prednisolone shelf life Subscription
The shelf life for Deltacortril (prednisolone; Alliance) and prednisolone (Alliance) gastro-resistant tablets 2.5mg has been increased from 24 to 36 months, according to the updated summaries of product characteristics.
Eliquis new indication Subscription
Eliquis (apixaban; Bristol-Myers Squibb) is now indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of reccurent DVT and PE, according to the updated summary of product characteristics. New information on the dosing of apixaban for these indications has also been added to the SPC.
Whistleblowing resource Subscription
The charity, Pharmacist Support, has launched a new fact sheet for pharmacists about whistleblowing. It covers topics such as how to deal with bullying after whistleblowing or dismissal from work after whistleblowing.
Adverse reactions for Roche's Herceptin Subscription
Nasopharyngitis, thrombocytopenia, weight loss, anorexia, insomnia, paraesthesia, dysgeusia, stomatitis, palmar-plantar erythrodysesthesia syndrome and peripheral oedema are now listed as very common adverse reactions on the summary of product characteristics for Roche’s Herceptin (trastuzumab). Pleural effusion, pharyngitis and pneumonia are now listed as common adverse reactions.
July EMA decisions Subscription
Janssen Cilag’s Imbruvica (ibrutinib) has been recommended for authorisation by the European Commission for the treatment of relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL), in this month’s decisions from the European Medicines Agency (EMA). Gilead’s Zydelig (idelalisib) has also been recommended for approval for the treatment of patients with CLL and patients with refractory follicular lymphoma.
Buccolam oromucosal solution recall Subscription
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a medicines recall for specific batches of ViroPharma’s Buccolam oromucosal solution (midazolam hydrochloride). This is because a routine inspection of the company’s contract manufacturing site in the UK identified the possibility of chemical contamination. Further information is available from the
Klaricid tablets discontinued Subscription
Abbott has discontinued Klaricid (clarithromycin) tablets 250mg x 14 and 500mg x 14. Further information on 01628 773355.
Leflunomide recall Subscription
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company-led drug recall for a specific batch of leflunomide (Medac) film-coated tablets 20mg. This is because the affected batch, which has inadvertently been distributed in the UK, is labelled for Poland/The Czech Republic/Slovakia. Further information is available from the
Changes to vaccine schedules Subscription
Public Health England has announced changes to the meningococcal C conjugate vaccination schedule. The primary vaccine should now be given to infants at three months, and boosters should be given at 12–13 months, around 14 years and to first-time university entrants from 1 August 2014. More detail is available on the PHE website.